Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • Uppercase wins the prestigious Red Dot award for its exceptionally designed suitcase, Bullet Business
  • Largest Indian design centre – The Colosseum launches in Hyderabad Business
  • COSTECH – ESYGO Joint Project to Set Up 2000 Electric Vehicle Charging Stations in Kerala Business
  • Sarvika Technologies launches eCommfy – An eCommerce platform for growing business Business
  • Effective Ways to Plan and Manage Your Educational Loan Repayment Finance
  • Sayba Group’s Strategic Redevelopment Projects to Transform Jogeshwari and Bandra West Business
  • Iconic Gold Awards Returns With Its 6th Edition To Celebrate Excellence In Film And Television Entertainment
  • Easy Build Announces Groundbreaking Pre-Launch Event: Pioneering a Building Material Revolution Business

Martin & Harris Labs reports robust results in FY21, PAT zooms 139% to Rs 177 Cr

Posted on January 15, 2022 By

New Delhi, January 15: Martin & Harris Laboratories, the pharmaceutical arm of Apeejay Group, has announced its results for the financial year ended on 31 March, 2021.

In the financial year 2020-21, Martin & Harris Laboratories clocked a profit after tax (PAT) of Rs 177 crore, a rise of 138.96% against a net profit of Rs 70 crore in the financial year 2019-20.

In the last seven years, the revenue of the company has grown at a CAGR of 30% and from Rs 67 crore to 336 crore, whereas PAT has surged at a CAGR of 61% to Rs 177 crore.

The total income for the FY 2020-21 includes Rs 138 crore from pharma business and Rs 196 crore from investment business. Earnings per share (EPS) of the company zoomed to 443 in FY21 against an EPS of 180 in FY20.

In FY21, Delite Infrastructure an investment arm of Martin and Harris Laboratory has generated EBIT of 160 Crores on capital of 400 Crores, which is 40% return on capital. And, though period and portfolio is large, if we benchmark this with Warren Buffet’s investment company Berkshire Hathaway, same has generated 20% CAGR return in the last 40 years. This shows that investment arm of Martin and Harris Laboratory is generating handsome return to shareholders.

Martin & Harris Laboratories have a couple of manufacturing facilities in Roorkee (Uttarakhand) and Una (Himachal Pradesh) wherein they manufacture some famous medicines like Drotin Plus, Amclox, Venusmin and Tamsin etc which are having high demand in the market. The company is constantly taking steps to modernize and expand its manufacturing units to meet international standards.

Apeejay Group was established in 1910 by Shri Pyare Lal Ji, which today has an annual turnover of more than Rs 2,500 Cr. From starting its journey in Jalandhar to manufacture steel goods for the domestic agriculture industry, today Apeejay Group has ventured into hotels, real estates, constructions, shipping and pharmaceuticals. Later on the legacy of Shri Pyare Lal was being carried out by his sons Surrendra and Stya. And, accordingly, the group was divided into two parts i.e. Apeejay Surrendra and Apeejay Stya Group.

Today, Apeejay Stya Group manages Martin and Harris Laboratory i.e. Pharma Business along with Apeejay Education Society and the Apeejay Stya Universities. Dr Stya Paul’s legacy of excellence is being carried forward by his daughter and only child, Mrs Sushma Paul Berlia, Chairman of the Apeejay Education Society.

Apeejay Surrendra Group business activities are presently oversee by his son and daughters i.e. Priya, Priti and Karan Paul.

Valuation

In the pre IPO market, the shares of Martin & Harris Laboratories are trading at Rs 2900-3000 apiece. With an average EPS of Rs 270 for the last three years, it commands a price to earnings (P/E) ratio little more than 10.75 to 11.11x.

On a standalone basis, the company’s pharma arm generated a net profit of Rs 40 crore in FY 2020-21 with an average EPS of Rs 102 for the last three years, it is trading at a P/E ratio of 28x. Nifty Pharma index is trading at a P/E ratio of 33x, there is ample upside left in the company.

Business Tags:Business

Post navigation

Previous Post: First-of-its-kind clinic launched in Lucknow to cure PCOD hormonal disorder in women
Next Post: IG Drones partners up with the Government of Gujarat at Pre-Vibrant Gujarat Summit

Related Posts

  • Online Pharmacy Trends Report 2024: Delhi Leads Searches, Mumbai Sees Growth Business
  • Formula E Race Delivered USD 84 Million Economic Benefit To Hyderabad Business
  • SETJA’s Yarn and Jari Textile Expo- 2024 in Surat Attracts 100 Exhibitors Nationwide Business
  • BoM Organises Meeting on the Customer Rights and Grievance Redressal Mechanism Under the RBI Nationwide Intensive Awareness Campaign Business
  • YES WORLD’s major event to SAVE EARTH held in New Delhi, attended by several Politicians and Climate Activists Business
  • NG-NeXT Embracing Change With The Excitement Of Onboarding Accomplished CSO Business

Recent Posts

  • How Vollsante Is Making Plant-Based Nutrition Mainstream
  • TGPS Infotech: Designing the Digital Framework for a Smarter, Sustainable Future
  • India Prepares to Celebrate Yoga Day at 81 Heritage Sites With Open Access for All
  • BudgetPe’s Digital Magic: Ankit & Rohit Fuel Rs 1,500 Cr Growth in 12 Months
  • “Beyond Compliance”: Vantage & Cyber Skillsphere to Launch New Standards in Cybersecurity Training

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Lemon Partners with Catfiz to Boost User Base by Over 5 Million UAE Business
  • International Women’s Day: Introducing Inspiring Women Leaders, Shaping the Future Business
  • Mir Nzam Ali Khan: Inspiring Hearts and Minds through Advocacy and Motivational Speeches Lifestyle
  • Legal Expert Sunil Kumar Pathak’s book Legal First Aid released at India International Centre Lifestyle
  • Gujarat based co-working player The Address eyeing giant expansion in 2022, all set to triple the existing capacity this year Business
  • Times Now Doctors Day Conclave: Experts call for ‘risk- grading’ of tobacco products in India Health
  • Global Environment and Climate Action Citizen Award conferred on Greenman Viral Desai Press Release
  • 99 Mobile Cover & Mart: From Android Developer to #1 Customised Mobile Cover Brand in India Lifestyle

Copyright © 2025 Daily News India.

Powered by PressBook News WordPress theme